CClinicalTrials.gg
CompletedNCT02732847Updated May 5, 2021Results posted

Trial of Post-Dated Delayed Antibiotic Prescriptions

An interventional study of A delayed prescription dated 2 days after clinical office visit and Usual Dated in Acute Upper Respiratory Tract Infections, sponsored by Memorial University of Newfoundland. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by Memorial University of Newfoundland · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Delayed prescriptions have been shown to lower antibiotic use for upper respiratory tract infections (which are mostly viral).

This trial will test the hypothesis that if the clinician post-dates the delayed prescription by 2 days, rather than dating it on the day the patient is seen, there will be a further drop in the rate of antibiotic use.

Read the detailed description

6 family doctors and 2 nurse practitioners in a small rural town will issue delayed antibiotic prescriptions to adult patients with new acute respiratory tract infections. The delayed prescriptions will be randomly dated for either the day of the office visit, or 2 days later. The 2 local pharmacies will note whether the prescription is cashed, and when.

It is hypothesised that post-dating the prescription will result in a reduced cashing rate.

Each arm of the study (Usual v Post-Dated) will contain 75 subjects. This sample will have the power to detect a 25% change in prescription use.

02

Conditions studied

  • Acute Upper Respiratory Tract Infections

Keywords

  • Respiratory infections
  • Primary care
  • Antibiotics
  • Delayed prescriptions
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 149 is above the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Memorial University of Newfoundland is the lead sponsor of 46 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults aged 18 years or older
  • Adults with an untreated upper respiratory tract infection
  • Adults presenting for the first time to a family physician or a nurse practitioner

Exclusion criteria

Exclusion Criteria:

  • Less that 18 years
  • Having a clear indication for antibiotic therapy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Other
    Post-Dated Prescription

    a delayed prescription dated 2 days after clinical office visit

    Other: A delayed prescription dated 2 days after clinical office visit

  • Other
    Usual

    usual date

    Drug: Usual Dated

Interventions

  • OtherA delayed prescription dated 2 days after clinical office visit
  • DrugUsual Dated
06

What researchers measure

Primary outcomes

  1. Number of Participants That Filled a Prescription in 20 Days

    Prescriptions

    Time frame: 20 days

07

Results

Posted May 5, 2021

Participant flow

Participant flow — Overall Study
MilestonePost-Dated PrescriptionUsual
Started7574
Completed3332
Not completed4242
Withdrew: Some filled early4242

Outcome measures

PrimaryNumber of Participants That Filled a Prescription in 20 Days

Prescriptions

Time frame:
20 days
Reported as:
Count of participants · Participants
Number of Participants That Filled a Prescription in 20 Days
ParticipantsPost-Dated PrescriptionUsual
Number of Participants That Filled a Prescription in 20 Days1616
Statistical analysis
  • Post-Dated Prescription vs Usual · Chi-squared · p = 0.924 (A p-value of \< 0.05 was considered)

Adverse events

Collected over This study did not involve reporting of adverse reactions over the 19 days time span. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Post-Dated Prescription———
Usual———

Baseline characteristics

This was an ad hoc study, and therefore no baseline information was recorded for this study design

Age, Categorical
Age, CategoricalPost-Dated PrescriptionUsualTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Sex: Female, Male
Sex: Female, MalePost-Dated PrescriptionUsualTotal
Female———
Male———
Race and Ethnicity Not Collected
Race and Ethnicity Not CollectedPost-Dated PrescriptionUsualTotal
08

Study locations

1 site
  • Memorial University
    St John's, Newfoundland and Labrador A0G 2L0, Canada
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02732847
Lead sponsor
Memorial University of Newfoundland
Responsible party
Sponsor
First posted
Apr 11, 2016
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
May 5, 2021
Last update
May 5, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion